Get the Stockscreener App
3.60
13.25%
-0.55
Citius Pharmaceuticals Inc Stock (CTXR) Latest News
Hemorrhoids Market Expected to Experience Major Growth by 2032, - openPR
Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma - Marketscreener.com
Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference - Marketscreener.com
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution - Marketscreener.com
Citius Pharmaceuticals, Inc. Appoints Jaime Bartushak as the Chief Financial Officer and Principal Financial Officer - Marketscreener.com
Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023 - Marketscreener.com
Citius Pharmaceuticals Engages Financial Advisor for Oncology Subsidiary Spinoff - Marketscreener.com
Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments - Marketscreener.com
Citius Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits - Quantisnow
Citius Pharma progresses with FDA on Mino-Lok approval By Investing.com - Investing.com Nigeria
Citius Pharmaceuticals (NASDAQ:CTXR) Earns Hold Rating from D. Boral Capital - Defense World
Citius Pharma progresses with FDA on Mino-Lok approval - Investing.com India
Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval - PR Newswire
Citius Pharmaceuticals Stock Set to Reverse Split on Tuesday, November 26th (NASDAQ:CTXR) - Defense World
Citius Pharmaceuticals Announces 1-for-25 Reverse Stock Split - citybiz
Citius Pharmaceuticals announces 1-for-25 reverse stock split - MSN
Citius Pharmaceuticals Announces 1-for-25 Reverse Stock Split to Maintain Nasdaq Listing | CTXR Stock News - StockTitan
Citius Pharmaceuticals stock hits 52-week low at $0.16 By Investing.com - Investing.com Australia
Citius Pharmaceuticals stock hits 52-week low at $0.16 - Investing.com India
Citius Pharmaceuticals reports positive early stage results of cancer combo treatment - MSN
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Update - Defense World
Citius Pharmaceuticals (NASDAQ: CTXR) Announces Successful Closure of Offering - Defense World
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering - BioSpace
Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share with Warrants | CTXR Stock News - StockTitan
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering - The Malaysian Reserve
Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share | CTXR Stock News - StockTitan
What is HC Wainwright’s Estimate for CTXR FY2024 Earnings? - Defense World
Citius Pharmaceuticals stock hits 52-week low at $0.31 By Investing.com - Investing.com South Africa
Citius Pharmaceuticals stock hits 52-week low at $0.31 - Investing.com
Equities Analysts Set Expectations for CTXR FY2024 Earnings - MarketBeat
What is HC Wainwright’s Forecast for CTXR Q1 Earnings? - Defense World
Citius Pharmaceuticals granted extension to regain Nasdaq compliance - Investing.com
Citius Pharmaceuticals granted extension to regain Nasdaq compliance By Investing.com - Investing.com Australia
Q1 Earnings Forecast for CTXR Issued By HC Wainwright - MarketBeat
Citius Pharmaceuticals (NASDAQ:CTXR) Receives Buy Rating from HC Wainwright - MarketBeat
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors - The Malaysian Reserve
Citius' LYMPHIR Shows Potential To Boost Pembrolizumab Efficacy - Contract Pharma
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors – Company An - Financial Times
Citius Pharmaceuticals stock hits 52-week low at $0.32 - Investing.com India
Citius Pharmaceuticals stock hits 52-week low at $0.32 By Investing.com - Investing.com UK
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR): Is Breakeven Near? - Simply Wall St
Citius Pharmaceuticals stock hits 52-week low at $0.34 By Investing.com - Investing.com Australia
Citius Pharmaceuticals stock hits 52-week low at $0.34 - Investing.com India
CTXR (Citius Pharmaceuticals) Cyclically Adjusted Revenue p - GuruFocus.com
Investing in Citius Pharmaceuticals Inc (CTXR) might be a great opportunity, but the stock is a bit undervalued - US Post News
Citius Pharmaceuticals Inc (CTXR) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Closing Bell Recap: Citius Pharmaceuticals Inc (CTXR) Ends at 0.37, Reflecting a -8.22 Downturn - The Dwinnex
There is no way Citius Pharmaceuticals Inc (CTXR) can keep these numbers up - SETE News
Citius Pharmaceuticals stock hits 52-week low at $0.39 By Investing.com - Investing.com Australia
Citius Pharmaceuticals stock hits 52-week low at $0.39 - Investing.com
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):